FDA Commissioner Warns Against "Illegal Copycat" Weight-Loss Drugs
FDA takes aim at compounded weight-loss drugs like Hims' $49 Wegovy alternative, raising safety concerns over unapproved copycat medications flooding the market.
/ 903 items
#Healthcare↓
Doximity Stock Plunges 30% on Weak Guidance and CFO Medical Leave
Doximity (DOCS) shares tumbled in premarket trading after the healthcare platform cut its revenue forecast and announced its CFO's temporary medical leave.
Molina Healthcare Plunges on Weak 2026 Profit Outlook
Molina Healthcare shares drop 29% after forecasting 2026 earnings at $5/share vs. Wall Street's $13.71 estimate, while exiting Medicare Part D amid rising medical costs.
Goldman Sachs Starts Coverage on Biohaven with Buy Rating
Goldman Sachs initiates coverage on Biohaven with a Buy rating and $23 price target, highlighting BHV-1400 and its potential in the large IgA nephropathy market.
Ginkgo & OpenAI Slash Protein Synthesis Costs by 40%
Ginkgo Bioworks teams up with OpenAI to cut cell-free protein synthesis costs by 40% using AI and cloud lab automation.
BofA Gives Wave Life Sciences a Buy Rating, Eyes $38 Target
Bank of America starts coverage of Wave Life Sciences (WVE) with a Buy rating. Analyst highlights WVE-007 in obesity as a major growth driver, with peak sales above $11B.